Ads
related to: regeneron antibody treatment- Dosing & Admin Info
Learn About The Recommended
Dosage For LIBTAYO®.
- View All Indications
Visit The HCP Site To Learn About
All Of The Approved Indications.
- Download Resources
Product and support information
for HCPs and patients.
- Patient Support Program
View information about the
LIBTAYO® patient support program.
- Mechanism of Action
Learn how LIBTAYO® works.
Read about treating patients.
- Contact A Representative
Contact a field rep today
for more info about LIBTAYO®.
- Dosing & Admin Info
Search results
Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected
Zacks via Yahoo Finance· 2 years agoRegeneron Pharmaceuticals, Inc. REGN posted better-than-expected first-quarter 2022 results, beating...
Regeneron's (REGN) Lymphoma Candidate Rejected by the FDA
Zacks via Yahoo Finance· 1 month agoRegeneron Pharmaceuticals, Inc. REGN suffered a setback as the FDA issued Complete Response Letters...
Is Regeneron In Trouble After Sales Declined 40% In a Single Quarter?
Motley Fool· 2 years agoRegeneron (NASDAQ: REGN) got a big boost last year due to COVID-19. But with demand for its antibody...
Regeneron (REGN) Q3 Earnings & Sales Top, Eylea Sales Decline
Zacks via Yahoo Finance· 6 months agoRegeneron Pharmaceuticals, Inc. REGN delivered better-than-expected third-quarter 2023 results, even...
Regeneron (REGN) Stock Rallies 10% YTD: What Lies Ahead?
Zacks via Yahoo Finance· 5 months agoShares of Regeneron REGN have gained 10.3% year to date against the industry’s decline of 14.8%....
Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss
Investor's Business Daily· 1 year agoRegeneron Pharmaceuticals handily beat Wall Street's third-quarter earnings estimate Thursday, but...
Regeneron Soars As Eylea Outplays Competition, Both Beating Forecasts And Growing
Investor's Business Daily· 2 years agoRegeneron Pharmaceuticals outplayed its competition in eye diseases Wednesday, reporting Eylea sales...
Regeneron (REGN) to Report Q2 Earnings: What's in Store?
Zacks via Yahoo Finance· 9 months agoRegeneron Pharmaceuticals, Inc. REGN is scheduled to release second-quarter 2023 results on Aug 3,...
Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker
Investor's Business Daily· 12 months agoThe struggles continued for Regeneron Pharmaceuticals' blockbuster eye disease treatment, Eylea, in...
Should You Sell This Stock Following a Regulatory Roadblock?
Motley Fool via Yahoo Finance· 3 weeks agoBiotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) has been on fire over the past three years....
Ad
related to: regeneron antibody treatment